OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

被引：0
|
作者：
Corman, J. [1 ]
Dawson, N. [2 ]
Hall, S. [3 ]
Nabhan, C. [4 ]
Ferrari, A. [5 ]
Armstrong, A. J. [6 ]
Murdock, M. I. [7 ]
Stewart, F. [8 ]
Sheikh, N. [9 ]
Petrylak, D. P. [10 ]
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Georgetown Univ, Washington, WA USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Murdock Urol Associates, Urol, Greenbelt, MD USA
[8] Dendreon Corp, Biometr, Seattle, WA USA
[9] Dendreon Corp, Clin Immunol, Seattle, WA USA
[10] Columbia Univ, Med Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [1] A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Small, Eric Jay
    Lance, Raymond
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Stubbs, Andrew
    McCoy, Candice
    DeVries, Todd
    Redfern, Charles H.
    Shore, Neal D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pill, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data
    Beer, Tomasz M.
    Glode, L. Michael
    Lance, Raymond S.
    Greengold, Richard H.
    Dela Rosa, Corazon P.
    Sims, Robert Brownell
    Wang, Yang
    Sheikh, Nadeem A.
    Corman, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC)
    Mulder, P.
    De Santis, M.
    Fizazi, K.
    Whitmore, J.
    Sheikh, N.
    McCoy, C.
    Stubbs, A.
    Powles, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [5] Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).
    Hepgur, Mehmet Faith
    Dorff, Tanya B.
    Cai, Jie
    Reed, Mary
    Chan, Betty
    Quinn, David I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Clinical and biologic factors for immune response to sipuleucel-T (SipT) for metastatic castrate-resistant prostate cancer (mCRPC)
    Hepgur, Mehmet Faith
    Dorff, Tanya B.
    Brining, Lucy
    Cai, Jie
    Pinski, Jacek K.
    Reed, Mary
    Luther, Michael
    Chan, Betty
    Quinn, David I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Clinical Evidence of the Immunologic Mechanism of Action (MOA)
    Nemunaitis, John
    [J]. MOLECULAR THERAPY, 2012, 20 : S131 - S131
  • [8] P10-1, an open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (rnCRPC) previously treated with sipuleucel-T: Analysis of immunological data
    Beer, T.
    Glode, M.
    Lance, R.
    Greengold, R.
    Haynes, H.
    Sims, R.
    Wang, Y.
    Sheikh, N.
    Corman, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S700 - S700
  • [9] P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation
    Beer, Tomasz M.
    Glode, L. Michael
    Lance, Raymond
    Greengold, Richard
    Sims, Robert Brownell
    Wang, Yang
    Sheikh, Nadeem A.
    Corman, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [10] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Radiation therapy (SAbR) for Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Dohopolski, M.
    Watumull, L.
    Mathews, D.
    Gao, A.
    Garant, A.
    Choy, H.
    Ahn, C.
    Timmerman, R. D.
    Courtney, K.
    Hannan, R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E879 - E879
12345